Show Sidebar Log in

Genescient Chairman to Speak at Singularity Summit 2009

Singularity Summit 2009Irvine, CA, August 24, 2009 — Gregory Benford, Chairman of the Board of Genescient Corporation, will speak at the Singularity Summit 09. The Singularity Summit is a gathering of visionaries in business, science, technology, design, and the arts, coming together to explore the rising impact of science and technology on society. This year’s Summit will take place on October 3 and 4 in Manhattan, and marks the first time that the Singularity Summit will be held on the East coast.

Benford will present on Genescient’s revolutionary approach to extended human longevity, with contiguous enhancements of vigor and function. Genescient is a California systems biology company founded on the use of artificial biological selection to cure the diseases of aging. Genescient’s laboratory animals were selectively bred for longevity over 750 generations – the equivalent of 15,000 human years.

The company’s approach addresses the complex genomic networks that underlie aging and aging-associated diseases such as cardiovascular disease, Type II diabetes and neurodegenerative diseases. Benford will discuss some of the company’s latest results and its upcoming products.

The Singularity Summit was founded by Tyler Emerson, Ray Kurzweil and Peter Thiel. Its objective is to to further understanding and discussion about the Singularity concept and the future of human technological progress.

Benford, a well-known scientist, author and innovator, retired from the University of California, Irvine’s Physics department to co-found Genescient. His presentations are scheduled for 10:15 AM and 1:35 PM, Sunday, October 4.

Learn more about The Singularity Summit 2009 here:
http://www.singularitysummit.com/

About Genescient Corporation:

Genescient Corporation is a California systems biology company using advanced information technology to study the genomics of aging and age-associated disease. Genescient applies 21st century genomic technology to identify, screen and develop benign therapeutic substances for the treatment of the chronic diseases of aging including cardiovascular disease, Type II diabetes, and neurodegenerative diseases.

Contact:

Damian Crowe, CEO
Genescient Corporation
+1 949-333-0058 x3305
http://Genescient.com

###

Comments are closed.